MedTrace Logo

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT02591095 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2019-03-19

No results posted yet for this study

Summary

ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.

Conditions

  • Platinum-resistant or Refractory Ovarian Cancer

Interventions

DRUG

ABT-263

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    collaborator OTHER

  • French Cancer Research Hospital Program

    collaborator UNKNOWN

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-04-30
Completion
2019-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02591095 on ClinicalTrials.gov